Sugi Predict

Sugi Predict / Compounds / SCHEMBL5759687

SCHEMBL5759687

SCHEMBL5759687

CCOC(=O)/C(N)=N/OC(=O)[C@H](CCCC1CCCCC1)CC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BMP1 P13497 5/20 0.37
▸ MMP2 P08253 4/20 0.37
▸ METAP2 P50579 1/20 0.36
▸ MMP3 P08254 2/20 0.35
▸ MMP1 P03956 1/20 0.35
▸ PPARG P37231 1/20 0.35
▸ PDE4A P27815 1/20 0.33
▸ PDE4B Q07343 1/20 0.33
▸ PDE4C Q08493 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HMGCR P04035 1/20 0.33
▸ FFAR1 O14842 1/20 0.32
▸ KDM5A P29375 2/20 0.32
▸ PHF8 Q9UPP1 2/20 0.32
▸ KDM2A Q9Y2K7 2/20 0.32
▸ KDM4C Q9H3R0 1/20 0.32
▸ KDM4A O75164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5759691 1.00 BMP1 (0.37) BMP1MMP2METAP2MMP3MMP1
SCHEMBL5403177 0.88 BMP1 (0.36) BMP1MMP2METAP2PPARGPDE4A
SCHEMBL5403174 0.88 BMP1 (0.36) BMP1MMP2METAP2PPARGPDE4A
SCHEMBL6429427 0.87 MMP2 (0.38) BMP1MMP2MMP3MMP1PDE4A
SCHEMBL6429432 0.87 MMP2 (0.38) BMP1MMP2MMP3MMP1PDE4A
SCHEMBL5403181 0.82 METAP2 (0.35) BMP1MMP2METAP2PPARGPDE4A
SCHEMBL6428654 0.78 MAPT (0.35) BMP1MMP2METAP2MMP3MMP1
SCHEMBL6428657 0.78 MAPT (0.35) BMP1MMP2METAP2MMP3MMP1
SCHEMBL5760320 0.77 BMP1 (0.38) BMP1MMP2MMP3MMP1
SCHEMBL5760317 0.77 BMP1 (0.38) BMP1MMP2MMP3MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343771-B1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2006-04-12 — — EP disclosed
EP-1373231-B1 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS PFIZER LTD (GB) 2005-06-08 — — EP disclosed
US-6897306-B2 3-heterocyclylpropanohydroxamic acids PFIZER PRODUCTS, INC. (US) 2005-05-24 — — US disclosed
EP-1373264-B1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2004-12-22 — — EP disclosed
US-6831088-B2 Wound healing agents; antiscarring agents PFIZER INC. 2004-12-14 — — US disclosed
EP-1240152-B1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LTD (GB) 2004-12-08 — — EP disclosed
US-6821972-B2 ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS PFIZER INC. 2004-11-23 — — US disclosed
US-6716861-B2 HETEROCYCLIC 1,2,4-OXADIAZOLE OR OXAZOLE RING CONTAINING PROPANOHYDROXAMIC ACIDS USEFUL AS ANTISCARRING AGENT PFIZER, INC. 2004-04-06 — — US disclosed
US-20040058917-A1 3-Heterocyclylpropanohydroxamic acid PCP inhibitors FISH PAUL VINCENT (GB) 2004-03-25 — — US disclosed
EP-1373264-A1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2004-01-02 — — EP disclosed
US-20030069291-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors PFIZER INC. 2003-04-10 — — US disclosed
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors FISH PAUL VINCENT (GB) 2002-12-12 — — US disclosed
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors PFIZER, INC 2002-10-17 — — US disclosed
WO-2002079200-A1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2002-10-10 — — WO disclosed
WO-2002079175-A1 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID PCP INHIBITORS PFIZER LIMITED (GB) 2002-10-10 — — WO disclosed
EP-1240152-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS Pfizer Limited (GB) 2002-09-18 — — EP disclosed
US-6448278-B2 ANTISCARRING AGENT PFIZER INC. 2002-09-10 — — US disclosed
WO-2002050046-A1 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2002-06-27 — — WO disclosed
US-20010021718-A1 Procollagen C-proteinase inhibitors PFIZER INC. 2001-09-13 — — US disclosed
WO-2001047901-A1 OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS PFIZER LIMITED (GB) 2001-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010021718-A1 Procollagen C-proteinase inhibitors MMP1, CTSL, PREP BMP1 166/4885MMP2 16/4885METAP2 214/4885
US-20040058917-A1 3-Heterocyclylpropanohydroxamic acid PCP inhibitors PAH, FAP, PREP BMP1 77/4885MMP2 34/4885METAP2 838/4885
US-20020187979-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors MMP1, CPA1, PAH BMP1 26/4885MMP2 28/4885METAP2 1039/4885
US-20020151535-A1 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors ALPI, TIMP3, MMP1 BMP1 376/4885MMP2 22/4885METAP2 532/4885
US-20030069291-A1 3-heterocyclylpropanohydroxamic acid PCP inhibitors PAH, CYP2F1, CYP7A1 BMP1 449/4885MMP2 3264/4885METAP2 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.